VIVA BIOTECH released its seventh ESG report, detailing 2025 operating and sustainability results.

Financial Performance • Revenue grew 21.31% year-on-year to RMB 1.73 billion. • Net profit reached RMB 269.30 million, up 21.30%. • Adjusted non-IFRS net profit rose 6.60% to RMB 335.30 million. • R&D expenditure totaled RMB 100.50 million; 60 % of employees are in R&D roles.

Operational & Governance Highlights • Board-level audit, remuneration and nomination committees oversee ESG and risk management. • Zero corruption or fraud cases; 100 % of employees completed integrity training. • Ninety-three start-ups incubated to date, with 231 active pipelines and 44 in clinical stages; 19 exits generated RMB 83.60 million cash in 2025 and RMB 205.10 million post-year-end.

Technology & Innovation • Launched proprietary AI-based AIDD platform featuring V-Scepter, V-Orb and V-Mantle modules; platform supports end-to-end drug design and large-scale licensing. • Cryo-EM structures exceeded 200; X-ray structures surpassed 98,000. • Cumulative patents in force: 82, with three new grants in 2025.

Environmental Metrics and Targets • Scope 2 greenhouse-gas emissions fell 5.80% to 39,401 tCO₂e; total Scope 1+2 emissions declined 7.07% to 39,870.76 tCO₂e. • Diesel use dropped 92.80% to 21,127 litres after fuel-switching to natural gas. • Non-hazardous waste generation decreased 10.26% to 748.04 tonnes. • Langhua Pharmaceutical set SBTi-validated goal to cut absolute Scope 1+2 emissions 42 % from 2023 levels by 2030; a three-phase roadmap combines efficiency upgrades, electrification, green heat and renewables procurement.

Social Indicators • Workforce: 2,169 employees (55 % male, 45 % female); 52 % under age 30. • Average training hours rose to 27.5 per employee; 66 % of staff received training. • Lost-time injury days totaled 781, with no fatalities reported in the past three years.

Supply Chain & Product Quality • Active supplier base: 2,119, 99 % located in Mainland China; annual audits cover ESG, quality and compliance. • No product recalls or major customer complaints; customer satisfaction scored 98/100.

Community & Talent Initiatives • Over RMB 41.00 thousand donated to community projects; 700 students engaged through internship bases and open-day programmes. • Employee benefits include housing support, flexible “care leave”, and long-term service bonus schemes; internal promotion reviews held semi-annually.

Looking Ahead The Board reiterates its commitment to embed ESG across strategy, scale AI-driven R&D, achieve a 42 % cut in Scope 1+2 emissions by 2030, and advance toward net-zero by 2050 while expanding one-stop CRO-to-CDMO services for global biopharma clients.